Phage therapy in clinical practice: Treatment of human infections

Current Pharmaceutical Biotechnology

Volumn 11, Issue 1, 2010, Pages 69-86

  Kutter, Elizabeth ^a   De Vos, Daniel ^b   Gvasalia, Guram ^c   Alavidze, Zemphira ^d   Gogokhia, Lasha ^e   Kuhl, Sarah ^f   Abedon, Stephen T ^g  

^a EVERGREEN STATE COLLEGE   (United States)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^c TBILISI STATE MEDICAL UNIVERSITY   (Georgia)

^d George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

Bacteriophages; Burn care; Eliava Institute; Hirszfeld Institute; Intestiphage; Osteomyelitis treatment; Phage therapy; Purulent infections; Pyophage; Wound care

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIOPHAGE; CLINICAL PRACTICE; EUROPE; GEORGIA (REPUBLIC); INFECTION; PHYSICIAN; REVIEW;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; HUMANS; VIRAL VACCINES;

EID: 77950166515     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110790725401     Document Type: Review

References (79)

1. Twort, F. W. An investigation on the nature of the ultramicroscopic viruses. Lancet, 1915, 186, 1241-1243.
2. d'Hérelle, F. Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. Ser. D, 1917, 165, 373-375.
3. Sulakvelidze, A.; Kutter, E. Bacteriophage therapy in humans. In: Bacteriophages: Biology and Application; Kutter, E., Sulakvelidze, A., Eds.; CRC Press: Boca Raton, Florida, 2005, pp. 381-436.
4. Bruynoghe, R.; Maisin, J. Essais de thérapeutique au moyen du bactériophage. Compt. Rend. Soc. Biol., 1921, 85, 1120-1121.
5. Wainwright, M.; Swan, H. T. C.G. Paine and the earliest surviving clinical records of penicillin therapy. Med. Hist., 1986, 30(1), 42-56.
6. Abedon, S. T.; Thomas-Abedon, C. Phage therapy pharmacology. Curr. Pharm. Biotechnol., 2010, 11(1), 28-47.
7. Gill, J. J.; Hyman, P. Phage choice, isolation and preparation for phage therapy. Curr. Pharm. Biotechnol., 2010, 11(1), 2-14.
8. st ed. Macmillan: Palgrave Macmillan, 2006, pp. 256.
9. Goodridge, L. D. Designing phage therapeutics. Curr. Pharm. Biotechnol., 2010, 11(1), 15-27.
10. Hyman, P.; Abedon, S. T. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol., 2010, 70.
11. d'Hérelle, F. Le Phénomène de la Guérison dans les Maladies Infectieuses, Masson et cie: Paris, 1938, p. 414.
12. Ackermann, H.-W.; DuBow, M. S. Phage multiplication. In: Viruses of Prokaryotes. General Properties of Bacteriophages; Ackermann, H.-W., DuBow, M. S., Eds.; CRC Press, Inc.: Boca Raton, Florida, 1987, Vol. I, pp. 49-85.
13. Chanishvili, N.; Sharp, R. A Literature Review of the Practical Application of Bacteriophage Research; Eliava Institute: Tbilisi, Georgia, 2009.
14. Chanishvili, N.; Sharp, R. Bacteriophage therapy: experience from the Eliava Institute, Georgia. Microbiol. Aust., 2008, 29 (2), 96-101.
15. Dubos, R. J.; Straus, J. H.; Pierce, C. The multiplication of bacteriophage in vivo and its protective effects against an experimental infection with Shigella dysenteriae. J. Exp. Med., 1943, 20, 161-168.
16. Górski, A.; Borysowski, J.; Miedzybrodzki, R.; Weber-Dabrowska, B. Bacteriophages in medicine. In: Bacteriophage: Genetics and Microbiology, McGrath, S., van Sinderen, D., Eds.; Caister Academic Press: Norfolk, UK, 2007, pp. 125-158.
17. Górski, A.; Miedzybrodzki, R.; Borysowski, J.; Weber-Dabrowska, B.; Lobocka, M.; Fortuna, W.; Letkiewicz, S.; Zimecki, M.; Filby, G. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs, 2009, 10 (8), 766-774.
18. Boratynski, J.; Syper, D.; Weber-Dabrowska, B.; Lusiak-Szelachowska, M.; Pozniak, G.; Górski, A. Preparation of endotoxin-free bacteriophages. Cell. Mol. Biol. Lett., 2004, 9 (2), 253-259.
19. Flack, J. C.; Girvan, M.; de Waal, F. B. M.; Krakauer, D. C. Policing stabilizes construction of social niches in primates. Nature, 2006, 439 (7075), 426-429.
20. Weber-Dabrowska, B.; Dabrowski, M.; Slopek, S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp., 1987, 35 (5), 563-568.
21. Dabrowska, K.; Switala-Jelén, K.; Opolski, A.; Weber-Dabrowska, B.; Górski, A. Bacteriophage penetration in vertebrates. J. Appl. Microbiol., 2005, 98 (1), 7-13.
22. Górski, A.; Wazna, E.; Dabrowska, B.-W.; Switala-Jelén, K.; Miedzybrodzki, R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol., 2006, 46 (3), 313-319.
23. Górski, A.; Weber-Dabrowska, B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell. Mol. Life Sci., 2005, 62 (5), 511-519.
24. Kucharewicz-Krukowska, A.; Slopek, S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch. Immunol. Ther. Exp., 1987, 35 (5), 553-561.
25. Weber-Dabrowska, B.; Czarny, A.; Mulczyk, M. Effect of bacteriophages on TNF-alpha, IL-6 and IFN production by human peripheral blood cells (PBC). Cytokine, 1999, 11 (11), 922.
26. Weber-Dabrowska, B.; Zimecki, M.; Mulczyk, M. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch. Immunol. Ther. Exp., 2000, 48, 31-37.
27. Weber-Dabrowska, B.; Zimecki, M.; Mulczyk, M.; Górski, A. Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol. Med. Microbiol., 2002, 34 (2), 135-138.
28. Górski, A.; Dabrowska, K.; Switala-Jelén, K.; Nowaczyk, M.; Weber-Dabrowska, B.; Boratynski, J.; Wietrzyk, J.; Opolski, A. New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol., 2003, 2, 2.
29. Górski, A.; Nowaczyk, M.; Weber-Dabrowska, B.; Kniotek, M.; Boratynski, J.; Ahmed, A.; Dabrowska, K.; Wierzbicki, P.; Switala-Jelén, K.; Opolski, A. New insights into the possible role of bacteriophages in transplantation. Transplant. Proc., 2003, 35 (6), 2372-2373.
30. Dabrowska, K.; Opolski, A.; Wietrzyk, J.; Switala-Jelén, K.; Boratynski, J.; Nasulewicz, A.; Lipinska, L.; Chybicka, A.; Kujawa, M.; Zabel, M.; Dolinska-Krajewska, B.; Piasecki, E.; Weber-Dabrowska, B.; Rybka, J.; Salwa, J.; Wojdat, E.; Nowaczyk, M.; Górski, A. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of β3 integrin signaling pathway. Acta virologica. English ed., 2004, 48 (4), 241-248.
31. Dabrowska, K.; Opolski, A.; Wietrzyk, J.; Switala-Jelén, K.; Godlewska, J.; Boratynski, J.; Syper, D.; Weber-Dabrowska, B.; Górski, A. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res., 2004, 24 (6), 3991-3995.
32. Kniotek, M.; Weber-Dabrowska, B.; Switala-Jelén, K.; Boratynski, J.; Wiszniewski, M.; Glinkowski, I.; Babiak, I.; Górecki, M.; Nowaczyk, M. Phages as immunomodulators of antibody production. In: Genomic Issues, Immune System Activation and Allergy (Immunology 2004), Monduzzi: Bologna, 2004.
33. Miedzybrodzki, R.; Fortuna, W.; Weber-Dabrowska, B.; Górski, A. Bacterial viruses against viruses pathogenic for man? Virus Res., 2005, 110 (1-2), 1-8.
34. Górski, A.; Kniotek, M.; Perkowska-Ptasinska, A.; Mroz, A.; Przerwa, A.; Gorczyca, W.; Dabrowska, K.; Weber-Dabrowska, B.; Nowaczyk, M. Bacteriophages and transplantation tolerance. Transplant. Proc., 2006, 38 (1), 331-333.
35. Pajtasz-Piasecka, E.; Rossowska, J.; Dus, D.; Weber-Dabrowska, B.; Zablocka, A.; Gorski, A. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett., 2008, 116 (1), 24-32.
36. Miedzybrodzki, R.; Fortuna, W.; Weber-Dabrowska, B.; Górski, A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin. Exp. Med., 2009, 9 (4), 303-312.
37. Fortuna, W.; Miedzybrodzki, R.; Weber-Dabrowska, B.; Górski, A. Bacteriophage therapy in children: Facts and prospects. Med. Sci. Monit., 2008, 14 (8), RA126-RA132.
38. Weber-Dabrowska, B.; Mulczyk, M.; Górski, A. Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev., 2001, 1 (3-4), 131-134.
39. Leszczynski, P.; Weber-Dabrowska, B.; Kohutnicka, M.; Luczak, M.; Górecki, A.; Górski, A. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker - a case report. Folia Microbiol., 2008, 51, 236-238.
40. Slopek, S.; Durlakova, I.; Weber-Dabrowska, B.; Kucharewicz-Krukowska, A.; Dabrowski, M.; Bisikiewicz, R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp., 1983, 31 (3), 267-291.
41. Slopek, S.; Durlakova, I.; Weber-Dabrowska, B.; Kucharewicz-Krukowska, A.; Dabrowski, M.; Bisikiewicz, R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evalulation of the results. Arch. Immunol. Ther. Exp., 1983, 31 (3), 293-327.
42. Slopek, S.; Durlakowa, I.; Weber-Dabrowska, B.; Dabrowski, M.; Kucharewicz-Krukowska, A. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch. Immunol. Ther. Exp., 1984, 32 (3), 317-335.
43. Slopek, S.; Kucharewicz-Krukowska, A.; Weber-Dabrowska, B.; Dabrowski, M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of results obtained in 370 cases. Arch. Immunol. Ther. Exp., 1985, 33 (2), 219-240.
44. Slopek, S.; Kucharewicz-Krukowska, A.; Weber-Dabrowska, B.; Dabrowski, M. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch. Immunol. Ther. Exp., 1985, 33 (2), 241-259.
45. Slopek, S.; Kucharewicz-Krukowska, A.; Weber-Dabrowska, B.; Dabrowski, M. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch. Immunol. Ther. Exp., 1985, 33 (2), 261-273.
46. Slopek, S.; Weber-Dabrowska, B.; Dabrowski, M.; Kucharewicz-Krukowska, A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp., 1987, 35 (5), 569-583.
47. Weber-Dabrowska, B.; Mulczyk, M.; Górski, A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc., 2003, 35 (4), 1385-1386.
48. Dublanchet, A. Des Virus Pour Combattre les Infections: La Phagothérapie, Favre: 2009.
49. Summers, W. C. Felix d'Herelle and the Origins of Molecular Biology, Yale University Press: New Haven, Connecticut, 1999.
50. Vieu, J.-F. Les bactériophages. In: Traité de Thérapeutique; Fabre, J., Ed.; Flammarion: Paris, 1975, pp. 337-340.
51. Vieu, J.-F.; Guillermet, F.; Minck, R.; Nicolle, P. Données actuelles sur les applications thérapeutiques des bactériophages. Bull. Acad. Natl. Med., 1979, 163 (1), 61-66.
52. Eaton, M. D.; Bayne-Jones, S. Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections (I). J. Am. Med. Assoc., 1934, 103, 1769-1776.
53. Krueger, A. P.; Scribner, E. J. The bacteriophage: Its nature and its therapeutic use (I). J. Am. Med. Assoc., 1941, 116, 2160-2167.
54. MacNeal, W. J.; Frisbee, F. C. One hundred patients with Staphylococcus septicemia receiving bacteriophage service. Am. J. Med. Sci., 1936, 191 (2), 179-195.
55. MacNeal, W. J.; Frisbee, F. C.; McRae, M. A. Staphylococcemia 1931-1940. Five hundred patients. Am. J. Clin. Pathol., 1942, 12, 281-294.
56. Morton, H. E.; Perez-Otero, E. J. The generation of dysentery bacteriophage in vivo during experimental infections with Shigella paradysenteriae, flexner, in mice. J. Bacteriol., 1944, 47, 475-476.
57. Esber, H. J.; DeCourcy, S. J., Jr.; Bogden, A. E. Specific and nonspecific immune resistance enhancing activity of staphage lysate. J. Immunopharmacol., 1981, 3 (1), 79-92.
58. Lincoln, R. E.; Mills, A. E. Unproven methods of cancer treatment. CA Cancer J. Clin., 1964, 14, 266-268.
59. Mills, A. E. Staphylococcus bacteriophage lysate aerosol therapy of sinusitis. Laryngoscope, 1956, 66 (7), 846-858.
60. Mills, A. E. Staphylococcus phage lysates: an immuno-biological therapy for the prevention and control of staphylococcal disease. Laryngoscope, 1962, 72, 367-383.
61. Smith, P. B.; Mudd, S. The Gratia polyvalent staphylococcal bacteriophage. Proc. Soc. Exp. Biol. Med., 1970, 134 (1), 225-229.
62. Larkum, N. W. Bacteriophage treatment of Staphylococcus infections. J. Infect. Dis., 1929, 45, 34-41.
63. Larkum, N. W. Production of antitoxins by means of bacteriophage. Am. J. Pub. Health, 1933, 23, 1155-1158.
64. Bruttin, A.; Brüssow, H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother., 2005, 49 (7), 2874-2878.
65. Soothill, J.; Hawkins, C.; Anggard, E.; Harper, D. Therapeutic use of bacteriophages. Lancet Infect. Dis., 2004, 4 (9), 544-545.
66. Wright, A.; Hawkins, C. H.; Angg+Ñrd, E. E.; Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryng., 2009, 34 (4), 349-357.
67. Altoparlak, U.; Erol, S.; Ackay, M.; Celebi, F.; Kadanali, A. The time-related changes of antimicrobial resistance patterns and pre-dominant bacterial profiles of burn wounds and body flora of burned patients. Burns, 2004, 30, 660-664.
68. Church, D.; Elsayed, S.; Reid, O.; Winston, B.; Lindsay, R. Burn wound infections. Clin. Microbiol. Rev., 2006, 19, 403-434.
69. Pirnay, J.P.; De Vos, D.; Cochez, C.; Bilocq, F.; Pirson, J.; Struelens, M.; Duinslaeger, L.; Cornelis, P.; Zizi, M.; Vanderkelen, A. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J. Clin. Microbiol., 2003, 41(3), 1192-1202.
70. Soothill, J. S. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns, 1994, 20, 209-211.
71. Jikia, D.; Chkhaidze, N.; Imedashvili, E.; Mgaloblishvili, I.; Tsitlanadze, G.; Katsarava, R.; Glenn Morris, J. J.; Sulakvelidze, A. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin. Exp. Dermatol., 2005, 30 (1), 23-26.
72. Marza, J. A. S.; Soothill, J. S.; Boydell, P.; Collyns, T. A. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns, 2006, 32 (5), 644-646.
73. Weber-Dabrowska, B.; Mulczyk, M.; Górski, A. Bacteriophage therapy of bacterial infections: An update of our institute's experience. Arch. Immunol. Ther. Exp., 2000, 48 (6), 547-551.
74. Abul-Hassan, H. S.; El-Tahan k Massoud, B.; Gomaa, R. Bacteriophage therapy of pseudomonas burn wound sepsis. Ann. Med. Burn Club, 1990, 3, 4, 262-264.
75. Markoishvili, K.; Tsitlanadze, G.; Katsarava, R.; Morris, J. G., Jr.; Sulakvelidze, A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol., 2002, 41 (7), 453-458.
76. Verbeken, G.; De Vos, D.; Vaneechoutte, M.; Merabishvili, M.; Zizi, M.; Pirnay, J.-P. European regulatory conundrum of phage therapy. Future Microbiol., 2007, 2 (5), 485-491.
77. Merabishvili, M.; Pirnay, J.-P.; Verbeken, G.; Chanishvili, N.; Tediashvili, M.; Lashkhi, N.; Glonti, T.; Krylov, V.; Mast, J.; Van Parys, L.; Lavigne, R.; Volckaert, G.; Mattheus, W.; Verween, G.; De Corte, P.; Rose, T.; Jennes, S.; Zizi, M.; De Vos, D.; Vaneechoutte, M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 2009, 4, 34944.
78. Taddonio, T. E.; Thompson, P. D.; Tait, M. J.; Prasad, J. K.; Feller, I. Rapid quantification of bacterial and fungal growth in burn wounds: biopsy homogenate Gram stain versus microbial culture results. Burns Incl. Therm. Inj., 1988, 14, 180-184.
79. Perez-Cappellano, R.; Manelli, J. C.; Palayret, D.; Carlin, G.; Echinard, C.; Jouglard, J. P. [Evaluation of septicemia risk in burn patients. Parallel between skin bacterial count and blood culture.]. Nouv Presse Med., 1976, 5 (29), 1831-1832.